<DOC>
	<DOCNO>NCT01590966</DOCNO>
	<brief_summary>In open-label monocentric explorative pilot trial objective show biodistribution TNFα administration radiolabeled anti-TNFα patient active rheumatoid arthritis spondylarthropathy . The anti-TNFα use trial certolizumab pegol ( Cimzia® ) , pegylated Fab'-fragment monoclonal antibody high specificity TNFα . Certolizumab pegol radiolabeled 99mTechnetium . The aim study show TNFα trigger inflammation process inflame joint , especially patient early joint damage currently image method X-rays sensitive enough detection .</brief_summary>
	<brief_title>Scintigraphic Detection Biodistribution Tumor Necrosis Factor With Radiolabeled Anti-TNFα Patients With Active Rheumatoid Arthritis Active Axial Peripheral Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>INCLUSION CRITERIA FOR RHEUMATOID ARTHRITIS PATIENTS ( 5 PATIENTS ) Age 18 70 yearsold document diagnosis ( clinical evaluation , xray hand foot minimum 2 month inclusion ) rheumatoid arthritis minimum 3 month maximum 15 year accord ACR criterion 1987 . At least 8 tender 8 swollen joint inadequate response least 2 diseasemodifying antirheumatic drug ( DMARDs ) one Methotrexate ( MTX ) . Methotrexate must administer least 3 month baseline dos route must stable least 2 month baseline . Minimum dosage MTX 10 mg weekly maximum dosage 25 mg weekly . HAQ ( Health assessment Score ) score least 25 baseline DAS 28 ( Disease Activity Score ) &gt; 3.7 baseline . All patient biological naïve patient . Negative Tuberculosis ( TB ) ( also history ) negative screen TB ( Mantoux test / xray thorax ) Female patient must postmenopausal least 1 year must undergo surgery become pregnant . Women child bear potential must use adequate contraception throughout study 12 week last dose certolizumab pegol . Patient need understand study sign inform consent form approve ethic committee participation study . INCLUSION CRITERIA FOR PATIENTS WITH AXIAL SPONDYLARTHROPATY ( 15 PATIENTS ) Age 18 70years old presence document diagnosis spondylarthropathy accord current ASAS criterion valid 3 subgroup ( early axial , early peripheral establish axial ) 10 patient axial SpA must fulfill current ASAS criterion AxSpA 5 need fulfill current modified New York criterion : Chronic low back pain &gt; 3 month onset age &lt; 45 year Active inflammatory injury sacroiliac joint MRI . Active inflammatory injury define oedema bone around sacroiliac joint , compatible active injury see axial SpA STIR ( short tau inversion recovery ) MRI Inadequate response previously , optimal use min 2 NonSteroidal AntiInflammatory Drugs ( NSAIDS ) antiinflammatory dosage 3 month medical contraindication use NSAIDs BASDAI score ≥ 4 5 patient peripheral SpA must presence clinical peripheral arthritis enthesitis dactylitis active disease activity , even stable dose sulfasalazine 3 month AND presence one following : Psoriasis skin Inflammatory bowel disease Positive HLA B27 sacroiliitis image ( Xray MRI sacroiliac joint ) patient antiTNF naive No active tuberculosis ( medical history current ) negative screen latent TB ( Mantoux test Xray thorax ) . Female patient must postmenopausal least 1 year must undergo surgery become pregnant . Women child bear potential must use adequate contraception throughout study 12 week last dose certolizumab pegol . Patient need understand study sign inform consent form approve ethic committee participation study . EXCLUSION CRITERIA FOR RHEUMATOID ARTHRITIS AND SPONDYLOARTHROPATHY PATIENTS Patients treatment experimental biological nonbiological therapy last 3 month 5times halflive prior baseline visit Patients previously treatment antiTNF Patients previously treatment rituximab and/or abatacept Known hypersensitivity certolizumab pegol ( Cimzia® ) one compound Current recent medical history progressive uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardial , neurological cerebral disease . Severe life threaten infection last 6 month ; sign current recent infection Active latent tuberculosis : case one 3 criterion positive : medical history TB , recent ( &lt; 6 month ) Xray chest recent positive PPD skin Known history current viral hepatitis B hepatitis C Known HIV infection Malignancy history malignancy History lymphproliferative disease signs/symptoms suggestive fort disease . Moderate severe hart failure ( NYHAclass III/IV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>spondyloarthritis</keyword>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>